Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | APP | P05067 | 5/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30746387 | 0.84 | CCR5 (0.46) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL26984849 | 0.84 | CCR5 (0.46) | NPC1RAB9AMAOBSMN1; SMN2LMNA | |
| SCHEMBL26985270 | 0.83 | AOC3 (0.55) | ABCB1SMN1; SMN2MAPTL3MBTL1IDO1 | |
| SCHEMBL22323905 | 0.81 | NPC1 (0.51) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL27037199 | 0.81 | NPC1 (0.51) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL1028222 | 0.79 | MAPT (0.53) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL3579056 | 0.76 | APP (0.50) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL16019002 | 0.75 | NPC1 (0.55) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL31013377 | 0.74 | NPC1 (0.54) | NPC1RAB9AAPPMAOBABCB1 | |
| SCHEMBL31613453 | 0.73 | ENPP2 (0.49) | MAOBLMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
| EP-1250326-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001053268-A2 | INDAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE FOR MEDIATING OR INHIBITING CELL PROLIFERATION | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | NPC1 2507/4885RAB9A 1411/4885APP 1977/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | NPC1 2507/4885RAB9A 1411/4885APP 1977/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | NPC1 2507/4885RAB9A 1411/4885APP 1977/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | NPC1 244/4885RAB9A 2583/4885APP 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.